Neuropeptide processing mutations and

<p> The paralytic response to aldicarb treatment was analyzed in strains containing mutations that inactivate pro-neuropeptide processing enzymes (<i>egl-3</i> PC2 and <i>egl-21</i> CPE), or those inactivating RIC-7. The number of trials (∼20 animals/trial) is shown for each genotype. Values that differ significantly from wild type (*, p<0.01; **, p<0.001, Students t-test) are indicated. Error bars indicate SEM. Values that are not significantly different are indicated (ns).